Cellectis (NASDAQ:CLLS) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a research note issued to investors on Wednesday morning. The firm issued a buy rating on the biotechnology company’s stock.

Separately, Barclays cut their price target on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th.

Cellectis Trading Down 0.6 %

NASDAQ CLLS opened at $1.53 on Wednesday. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. Cellectis has a 1-year low of $1.41 and a 1-year high of $3.38. The firm’s fifty day simple moving average is $1.63 and its 200-day simple moving average is $1.91. The company has a market capitalization of $85.04 million, a PE ratio of -1.18 and a beta of 3.06.

Hedge Funds Weigh In On Cellectis

Hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN raised its stake in shares of Cellectis by 103.4% in the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 12,500 shares in the last quarter. Millennium Management LLC bought a new position in Cellectis in the 4th quarter worth $962,000. Finally, B Group Inc. acquired a new stake in shares of Cellectis in the fourth quarter valued at about $5,547,000. 63.90% of the stock is owned by institutional investors and hedge funds.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.